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of systematic reviews
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Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Aller‑
gen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we 
sought to critically assess the systematic review evidence on the effectiveness, safety and cost‑effectiveness of AIT for 
ARC.
Methods: We undertook a systematic overview, which involved searching nine international biomedical databases 
from inception to October 31, 2015. Studies were independently screened by two reviewers against pre‑defined eligi‑
bility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist 
for systematic reviews. Data were descriptively synthesized.
Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met 
our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews 
suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in 
significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both 
SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT 
and SLIT.
Conclusions: We found moderate‑to‑strong evidence that SCIT and SLIT can, in appropriately selected patients, 
reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does 
however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and 
protocols studied . There is a lack of data on the relative effectiveness, cost‑effectiveness and safety of SCIT and SLIT. 
We are now systematically reviewing all the primary studies, including recent evidence that has not been incorpo‑
rated into the published systematic reviews.
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Background
Allergic rhinoconjunctivitis (ARC) is a very common 
chronic condition that can result in considerable morbidity 
and impairment in quality of life [1–3]. The disease is trig-
gered by exposure to seasonal and/or perennial allergens 
and, depending on the nature of the allergenic trigger(s) 
and patterns of exposure, symptoms may be intermit-
tent, persistent or persistent with intermittent exacerba-
tions [4]. Allergic rhinitis (AR) is typically characterized by 
symptoms of nasal obstruction, a watery nasal discharge, 
sneezing and itching; there is also often involvement of the 
conjunctiva, which manifests with itching, injection of the 
conjunctiva and tearing [5]. In addition, there may be an 
impact on the ability to concentrate, an adverse impact on 
school and work performance [6, 7], and interference with 
daily activities and sleep; allergic rhinitis is a risk factor for 
the development of asthma [8].
In most cases, symptoms can be controlled with 
attempts to avoid the allergenic trigger and pharmaco-
therapy, including oral, intranasal and  H1-antihistamine 
eye drops, intranasal corticosteroids and anti-leukot-
rienes; these agents can be used as monotherapy or in 
combination [4, 9, 10]. Allergen immunotherapy (AIT) 
is an additional treatment option for those with trouble-
some disease that remains inadequately controlled by 
other therapies [11–13]; it has also been shown to have 
a disease modifying effect [14]. The problem of uncon-
trolled ARC, despite maximum medical treatment, 
continues to represent a therapeutic challenge in some 
patients [15].
We are undertaking a comprehensive, systematic 
synthesis of the evidence in relation to AIT for ARC to 
inform new European Academy of Allergy and Clinical 
Immunology (EAACI) Guidelines on Allergen Immuno-
therapy (AIT) for ARC. Due to the volume of primary 
trial data available for ARC, we have divided the evi-
dence synthesis process into an initial systematic over-
view of the previous published systematic reviews. This 
will be followed by a second review focusing on the pri-
mary studies. This initial paper aims to provide a rigorous 
overview of current systematic review evidence on the 
effectiveness, safety and cost-effectiveness of AIT [16]. A 
second publication will focus on a systematic review of 
the primary publications.
Methods
This systematic overview of systematic reviews was con-
ducted and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines (Additional file 1: Appen-
dix 3). Our protocol is registered with the PROSPERO 
International Prospective Register of Systematic Reviews 
(CRD42016035373), which is reported in full in Clinical 
and Translational Allergy [17]. We therefore confine 
ourselves here to providing a synopsis of the methods 
employed.
Search strategy
A highly sensitive search strategy was developed and vali-
dated study design filters were applied to retrieve articles 
pertaining to the use of AIT for ARC from electronic bib-
liographic databases. We used the systematic review filter 
developed at McMaster University Health Information 
Research Unit (HIRU) [18].
We searched the following databases: Cochrane 
Library including, Cochrane Database of Systematic 
Reviews (CDSR), Database of Reviews of Effectiveness 
(DARE), CENTRAL (Trials), Methods Studies, Health 
Technology Assessments (HTA), Economic Evaluations 
Database (EED), MEDLINE (OVID), Embase (OVID), 
CINAHL (Ebscohost), ISI Web of Science (Thomson 
Web of Knowledge), TRIP Database (http://www.tripda-
tabase.com).
The search strategy was developed on OVID MED-
LINE and then adapted for the other databases (see Addi-
tional file  1). In all cases, the databases were searched 
from inception to October 31, 2015. Additional refer-
ences were located through searching the references 
cited by the identified studies, and unpublished work, 
while research in progress was identified through dis-
cussion with experts in the field. There were no language 
restrictions employed; where possible, relevant literature 
was translated into English.
Inclusion criteria
Patient characteristics
We focused on systematic reviews of studies conducted 
on patients of any age with a physician-confirmed diag-
nosis of ARC or AR, plus evidence of clinically relevant 
allergic sensitization (e.g., skin prick test or specific-IgE).
Interventions of interest and comparator
We were interested in AIT for relevant allergens in ARC 
(e.g. pollen, house dust mites, animal dander, cockroach 
and molds), including modified allergens. These could 
have been administered through any route (e.g. subcu-
taneous (SCIT), sublingual (SLIT), oral (OIT), intranasal 
(LNIT), epicutaneous, intradermal or intra-lymphatic) 
compared with placebo or any active comparator.
Study designs
We were interested in evidence from systematic reviews.
Study outcomes
The primary outcome of interest was measures of short-
term (i.e. during treatment) and long-term (i.e. at least a 
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year after discontinuation of AIT) measures of effective-
ness assessed by symptom and/or medication scores [16].
Secondary outcomes of interest included: assessment of 
disease specific quality of life; threshold of allergen expo-
sure to trigger symptoms in an environmental exposure 
chamber or allergen challenge; safety as assessed by local 
and systemic reactions in accordance with the World 
Allergy Organization’s grading system of side effects [19, 
20]; and health economic analyses from the perspective 
of the health system/payer.
Study selection
All references were uploaded into the systematic review 
software DistillerSR and underwent initial de-duplica-
tion. Study titles were independently checked by two 
reviewers (UN and SD) according to the above selection 
criteria and categorized as: included, not included or 
unsure. For those papers in the unsure category, abstracts 
were retrieved and re-categorized as above. Any discrep-
ancies were resolved through discussion and, if necessary, 
a third reviewer was consulted (AS). Full text copies of 
potentially relevant studies were obtained and their eli-
gibility for inclusion independently assessed. Studies that 
did not fulfil all of the inclusion criteria were excluded.
Quality assessment strategy
Quality assessments were independently carried out on 
each systematic review by two reviewers (UN and SA) 
using the relevant version of the Critical Appraisal Skills 
Programme (CASP) quality assessment tool for system-
atic reviews [21]. Any discrepancies were resolved by 
discussion or, when agreement could not be reached, 
arbitration by a third reviewer (SD).
Data extraction, analysis and synthesis
Data were independently extracted onto a customized 
data extraction sheet in DistillerSR by two reviewers (UN 
and SA), and any discrepancies were resolved by discus-
sion or, if agreement could not be reached, by arbitration 
by a third reviewer (SD). We produced a descriptive sum-
mary with data tables to support a narrative synthesis of 
the data.
Results
Characteristics of included systematic reviews
Our searches yielded a total of 5932 potentially eligible 
systematic reviews and primary studies. Twenty-two 
potential systematic reviews were identified; five of these 
were however conference papers (n = 4) and a report on 
a systematic review (n = 1). Seventeen reviews met our 
inclusion criteria (see PRISMA flow diagram, Fig. 1). We 
were unable to obtain a translation for one of the reviews 
[30].
These 17 systematic reviews included synthesis of data 
from 466 randomized controlled trials (RCTs), of which 
~300 were unique (we were unable to be more specific 
because not all of these systematic reviews provided a 
comprehensive list of included studies; see Additional 
file  2: Table S1). There were four systematic reviews 
investigating SCIT [22–25], eight SLIT [26–33], four 
both SCIT and SLIT [34–37], and one investigating sev-
eral different routes of administration of AIT including 
SCIT, SLIT, OIT and LNIT [38].
The majority of systematic reviews were led by teams 
from the UK (n = 5) [25, 29, 31, 34, 36], followed by the 
USA (n = 4) [22, 24, 28, 35], Italy (n = 3) [26, 27, 32], the 
Netherlands (n = 2) [30, 38], China (n = 2) [23, 33], and 
Canada (n = 1) [37]. Twelve systematic reviews included 
participants of any age (i.e. children and adults) [22–29, 
31, 34, 36, 37], four included children aged up to 18 years 
of age [32, 33, 35, 38].
In nine of the systematic reviews, data were pooled and 
the results of meta-analyses were provided (see Table 1) 
[22, 25–27, 29, 31, 33, 34, 37]. 
Quality assessment of systematic reviews
Quality assessment of these systematic reviews is sum-
marized in Table  2. Overall, the quality of included 
reviews were high to moderate, with only three studies 
being judged as being of low quality. Eight studies were 
considered at low risk of bias [23–25, 27, 29, 32, 34, 36], 
five studies were at moderate risk of bias [22, 26, 28, 33, 
35], and three were judged as being at high risk of bias 
[31, 37, 38]. We then used a modified version of the 
World Health Organization’s Health Evidence Network 
system, as employed by Black et  al. [39], for appraising 
evidence, which classifies evidence into strong, moderate 
or weak; this assessment being based on a combination of 
the overall consistency, quality, and volume of evidence 
uncovered (see Table 3).  
SCIT
Effectiveness of SCIT as assessed by symptom and medication 
scores
ARC symptom scores There were four studies that eval-
uated the effectiveness of SCIT in children and adults 
[22–25]. The quality of evidence from included system-
atic reviews was high. Calderon et al., conducted a high 
quality Cochrane systematic review of SCIT for seasonal 
allergic rhinitis (SAR) covering studies up to 2006 [25]. 
Meta-analysis from 15 RCTs demonstrated a significant 
reduction in symptom score (SS) (SMD −0.73 (95% CI 
−0.97 to −0.50, P  <  0.00001) in the intervention group 
when compared to placebo. The systematic review by 
Erokosima et  al., judged to be of moderate quality, cov-
ered studies to 2012; it reported that 20 out of 23 included 
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RCTs consistently showed greater SS improvement in the 
SCIT group than the comparator arm (usual care) [22]. 
Purkey et al., who analyzed data from 12 RCTs up to 2011 
narratively, reported a significant decrease in allergic rhi-
nitis symptom scores [24].
The high quality meta-analysis by Feng et  al., which 
included eight cluster SCIT RCTs published up to 2013, 
however found that four trials demonstrated no signifi-
cant difference in SSs compared to placebo: weighted 
mean difference (WMD)  =  −5.91 (95% CI −13.68 to 
1.87; P = 0.14) [23].
Kim et al., evaluated three RCTs published up to 2012 
with 285 pediatric patients with AR or ARC symptom 
scores and reported moderate strength evidence that 
SCIT controls AR or ARC symptoms better than placebo 
[35].
ARC medication scores The systematic review and meta-
analysis by Calderon et  al. found that AIT significantly 
decreased medication scores (MS) with a SMD of −0.57 
(95% CI −0.82 to −0.33, P < 0.00001) [25]. In the review by 
Erekosima et al., ten studies including 564 subjects found 
moderate evidence that SCIT decreased medication use 
in ARC [22]. However, combined symptom-medication 
scores (SMS) from six studies with 400 participants found 
only weak evidence to support that SCIT improves SMS. 
Feng et al. found no significant differences in MS between 
cluster SCIT versus placebo: combined WMD −1.27 (95% 
CI −2.83 to 0.29, P  =  0.11) and WMD −0.01 (95% CI 
−0.16 to 0.13, P = 0.88), respectively [23]. Another high 
quality systematic review in this category by Purkey et al., 
in a descriptive analysis demonstrated that SCIT for AR 
significantly improved MS [24].
Effects of SCIT on secondary outcomes
Assessment of  disease specific quality of  life (QoL) The 
review by Calderon et al. reported a clinically and statisti-
cally significant improvement in disease specific QoL in 
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the immunotherapy group compared with placebo (SMD 
−0.52, 95% CI −0.69 to −0.34, P =  0.00001) [25]. Ere-
kosima et  al., who used the Rhinoconjunctivitis Quality 
of Life Questionnaire (RQLQ) and/or the Short Form 36 
(SF36) questionnaire, also found high quality evidence 
to support the use of SCIT to improve disease-specific 
QoL (n =  539) for rhinitis/rhinoconjunctivitis [22]. The 
meta-analysis conducted by Feng et al., demonstrated that 
cluster SCIT was superior to placebo in improving over-
all QoL in two included studies (n = 104; WMD −0.79, 
95% CI −1.10 to −0.47, P < 0.00001) [23]. Finally, Purkey 
et al., also found that, in four studies all of which used the 
RQLQ, that SCIT improved the QoL measure in patients 
with AR [24].
Threshold of  allergen exposure to  trigger symptoms 
in an environmental exposure chamber or allergen chal-
lenge Two reviews investigated the impact on challenge 
tests [24, 25]. Calderon et al., reported an increase in the 
allergen provocation dose for the active treatment com-
pared with placebo in 13 RCTs. 21 studies performed skin 
challenges and reported a reduction in the skin reactiv-
ity after SCIT [25]. However, in the more recent review, 
Purkey et  al. reported conflicting results: one included 
RCT showed a reduction in immediate or delayed cuta-
neous responses grass pollen SCIT, two other RCTs also 
showed a reduction in symptoms in conjunctival provoca-
tion tests, but two other studies did not show any differ-
ences on either nasal provocation testing or skin reactivity 
to HDM results between active and placebo groups [24].
Safety The Cochrane review by Calderon et al., demon-
strated that SCIT had a low risk of severe adverse events. 
There were no fatalities in the included RCTs. Adrena-
line (epinephrine) was given in 0.13% (19 of 14,085 injec-
tions) of those on SCIT and in 0.01% (1 of 8278 injec-
tions) of the placebo group for the treatment of adverse 
events (AEs) [25]. Erekosima et  al. reported both local 
and systemic reactions: local reactions were common 
(5–58% participants, 3–10% injections); the most com-
mon systemic reactions were respiratory reactions (not 
broken down into upper or lower respiratory symptoms) 
(71% patients in the active group versus 88% in com-
parator group; up to 27% injections); there were 13 ana-
phylactic reactions in four RCTs and no fatalities were 
reported [22]. Purkey et al., reported that administering 
SCIT was safe in suitably selected patients and settings 
capable of responding to emergency situiations [24]. 
Feng et al., graded adverse events based on the European 
Academy of Allergology and Clinical immunology Posi-
tion Paper: [40] no differences in local reactions between 
cluster SCIT and placebo (the combined risk difference 
(RD) 0.00, 95% CI −0.00 to 0.01, P = 0.40) with the same 
trend for systemic reactions (RD 0.00, 95% CI −0.00 to 
0.01, P = 0.24) [24].
Comparative effectiveness of different AIT regimens Two 
systematic reviews reported the comparison between dif-
ferent AIT regimens. Erekosima et al., assessed 23 SCIT 
RCTs, 20 of which showed a greater improvement in the 
SCIT group, two of these involved an active compari-
son: one compared SCIT with pharmacotherapy and the 
second trial compared with another unspecified control 
group [22]. Feng et al., also compared cluster SCIT versus 
conventional SCIT. There were no differences on SS or MS 
between cluster SCIT versus conventional SCIT: WMD 
0.16, 95% CI −0.18 to 0.51; P = 0.36 and WMD −0.01, 
95% CI −0.16 to 0.13, P  =  0.88, respectively [23]. The 
incidence of local and systemic adverse reactions between 
cluster SCIT versus conventional SCIT also demonstrated 
no differences between these two groups (combined RR 
1.13, 95% CI 0.63–2.03, P =  0.68, and RR 0.99, 95% CI 
0.52–1.91, P = 0.98, respectively) [23].
Health economic analysis There were no systematic 
reviews that reported on health economic outcomes.
Table 3 Summary of evidence to support the effectiveness 
of AIT
Effectiveness is overall referred to symptom and medication scores unless 
otherwise stated
+++, Strong evidence; ++, Moderate evidence; +, Some/limited evidence; 
+/−, Unclear evidence; –, No evidence; SS, symptom scores; MS, medication 
scores
a Same results were referred also to oral immunotherapy and intranasal 
immunotherapy
Study ID SLIT SCIT
Calderon et al. [25] NA +++
Di Bona et al. [27] +/− NA
Di Bona et al. [26] +/− NA
Dranitsaris et al. [37] ++ (indirect analysis) NA
Dretzke et al. [36] +++ +++
Erekosima et al. [22] NA ++/+++
Feng et al. [23] NA –
Kim et al. [35] ++ ++
Lin et al. [28] ++ NA
Meadows et al. [34] ++ (only in adults) ++ (only in adults)
Purkey et al. [24] NA +++
Radulovic et al. [29] ++/+++ NA
Röder et al. [38] a – –
Sopo et al. [32] +/++ NA
Wilson et al. [31] ++ (only in adults) NA
Zhang (2014) ++ (MS)/− (SS) NA
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SLIT
Effectiveness of SLIT as assessed by symptom and medication 
scores
ARC symptom scores Two systematic reviews and meta-
analyses were conducted by Di Bona et  al. In their first 
review (trials up to 2010) they reported that SLIT with 
grass pollen for SAR significantly reduced symptom scores 
(SMD −0.32, 95% CI −0.44 to −0.21, P < 0.0001) com-
pared to placebo [26]. This was confirmed in their more 
recent (trials up to 2014) systematic review and meta-
analyses in which they also reported a significant reduc-
tion symptom score in the active group compared with 
placebo (SMD −0.28, 95% CI −0.37 to −0.19, P < 0.01) 
[27]. This second review only included RCTs using SLIT 
in tablet form. Three other systematic reviews and meta-
analyses also reported the impact of SLIT on AR or ARC 
symptom scores [29, 31, 33]. One meta-analysis (trials 
up to 2002) and a subsequent update (trials up to 2009) 
showed significant reductions in symptoms score in the 
SLIT group compared to placebo (SMD −0.42, 95% CI 
−0.69 to −0.15, P = 0.002 and SMD −0.49, 95% CI −0.64 
to −0.34, P  <  0.0001, respectively) [29, 31]. The third 
more recent (trials up to 2014) meta-analysis focusing 
just on children reported that there were no differences 
between intervention and placebo groups (SMD 0.06, 95% 
CI −0.13 to 0.25, P = 0.55) [33]. The other two reviews 
reported a narrative synthesis of RCTs: either moderate 
evidence that SLIT decreases AR or ARC symptoms, with 
nine of 36 included RCTs (up to 2012) reported greater 
than 40% improvement versus the comparator group [28] 
or no beneficial effect from SLIT in pediatric patients with 
AR in an older review (trials up to 2003) [32].
ARC medication scores The two reviews by Di Bona 
et  al. provided evidence that SLIT significantly reduced 
medication usage (SMD −0.33, 95% CI −0.50 to −0.16, 
P < 0.0001 and −0.24, 95% CI −0.31 to −0.17, P < 0.01, 
respectively) [26, 27]. A similar reduction in MS was 
seen in three other systematic reviews and meta-analyses 
(SMD −0.32, 95% CI −0.43 to −0.21, P  <  0.00001 [29], 
SMD −0.43, 95% CI −0.63 to −0.23, P =  0.00003 [31], 
SMD −0.61, 95% CI −0.94 to −0.27, P = 0.0004 [33] com-
pared with placebo). Lin et al., in a qualitative synthesis 
of RCTs, found that 38 of 41 studies (93%) found greater 
improvement in MS in the active group compared with 
the comparator group, with 16 studies demonstrating a 
strong effect [28].
Effects of SLIT on secondary outcomes
Assessment of  disease specific QoL Two systematic 
reviews assessed the effects of AIT on disease-specific 
QoL. Radulovic et  al. found three studies that reported 
QoL, but assessments differed too much to allow them to 
include the data [29]. Lin et al. reported disease-specific 
QoL in eight studies involving 819 participants; seven of 
eight demonstrated a favorable change in the SLIT group 
compared with placebo [28].
Threshold of  allergen exposure to  trigger symptoms 
in an environmental exposure chamber or allergen chal-
lenge One systematic review reported allergen sensitiv-
ity issues [31]. 13 RCTs measured cutaneous sensitivity 
and four studied nasal sensitivity. Seven studies reported 
no significant difference between active and placebo 
groups and in six studies, there was no comparison with 
placebo or relevant data presented.
Safety Safety analysis of SLIT was reported in five sys-
tematic reviews [26–29, 31]; meta-analysis of data was 
reported in one of these systematic reviews [33]. Di Bona 
et  al. reported a total of 4856 treatment-related AEs 
[3286 (2.6 AEs/patient) in the SLIT group and 1570 (1.34 
adverse events/patient) in the placebo group]. The major-
ity of adverse events were moderate; 3% in the SLIT group 
and 0.7% in the placebo group patients withdrew because 
of treatment-related adverse events [26]. The more recent 
review from the same research group demonstrated that 
adverse events were reported in 1384 of 2259 patients 
(61.3%) receiving SLIT and in 477 of 2279 patients (20.9%) 
receiving placebo. Withdrawal rate was higher in the SLIT 
group (6.0%) than in the placebo group (2.2%). No epi-
sodes of anaphylaxis were reported and seven patients 
required the use of adrenaline for systemic adverse events. 
(2) Lin et al. reported that local reactions were more fre-
quent in the SLIT group (range 0.2–97%) than in the com-
parator groups (range 3–38.5%). There were no episodes 
of anaphylaxis or fatalities in any treated patients across 
studies [28].
The updated Cochrane review highlighted that the lack 
of a standardized grading system for reporting of AEs 
associated with SLIT made conducting meta-analysis 
impractical. None of the included RCTs reported severe 
systemic reactions, anaphylaxis or use of adrenaline [29]. 
Wilson et al., indicated that there were no systemic reac-
tions in the RCTs. Minor local reactions, such as itching 
and swelling of the oral mucosa, were however reported 
almost in every included study [31]. The only systematic 
review and meta-analysis that pooled adverse events data 
quantitatively reported that there was no difference in 
the incidence of adverse events between active and pla-
cebo groups (OR 1.3, 95% CI 0.89–1.90, P = 0.17) [33].
Health economic analysis There were no systematic 
reviews that reported on health economic outcomes.
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SCIT versus SLIT
There were four systematic reviews comparing SCIT 
and SLIT [34–37]; three of these also conducted indirect 
analysis of efficacy, safety and cost of SCIT versus SLIT 
[34, 36, 37]. The study by Dranitsaris et al. also employed 
an indirect analysis of efficacy, safety and cost of SLIT or 
SCIT for SAR [37].
Effectiveness as assessed by symptom and medication scores
ARC symptom scores Dretzke et al. conducted a system-
atic review and indirect comparison (SCIT vs. SLIT) of 
included studies [36]. In studies where SCIT was com-
pared with placebo, SCIT significantly decreased SS 
(SMD −0.65, 95% CI, −0.85 to −0.45, P < 0.00001. Indi-
rect comparison based on one small low quality head-to-
head RCT reported that standardized score difference for 
SS between SCIT versus SLIT was in favor of SCIT: 0.35, 
95% CI 0.13–0.59. A HTA of SCIT and SLIT in adults and 
children with SAR demonstrated statistically significant 
effects of SCIT and SLIT compared with symptomatic 
treatment or placebo; of relevance, here however is that 
an indirect comparison suggested that SCIT was more 
effective than SLIT [34].
ARC medication scores In an indirect comparison between 
SCIT and SLIT, the overall standardized score differences 
(SSDs) was 0.27 (95% CI 0.03–0.53) in favor of SCIT. SCIT 
also significantly reduced the combined symptom and 
medication score (SMS) (SMD −0.48 (95% CI −0.67 to 
−0.29, P  <  0.00001)). Indirect comparison between SCIT 
and SLIT showed no difference in SMS between them (SSD 
0.31, 95% CI −0.195.8 to 194.1) [26]. Kim et al., compared 
MS between SCIT and SLIT in children with asthma and 
ARC in 13 studies with 1078 participants. The strength of 
evidence was moderate that SLIT decreases medication 
use for the affected patients, but only low for SCIT [35]. A 
Health Technology Assessment (HTA) systematic review 
reported statistically significant results for SCIT and SLIT 
on MS [34]. An indirect comparison analysis between SCIT 
and SLIT found that SCIT was more beneficial for MS com-
pared with SLIT, but this was associated with substantial 
residual heterogeneity of included studies.
Disease specific quality of  life Dretzke et  al., reported 
that SCIT and SLIT improved disease specific QoL scores 
in patients with SAR when compared to controls (SMD 
−0.53, 95% CI −0.66 to −0.39, P  <  0.00001 and SMD 
−0.37, 95% CI −0.52 to −0.22, P < 0.00001, respectively) 
[36]. There was however no differences in the impact on 
disease specific QoL scores between SCIT and SLIT tri-
als (SSD 0.38, 95% CI −0.04 to 0.80). An HTA review 
reported beneficial effects of SCIT or SLIT on the QoL 
scores in patients with SAR compared with placebo; how-
ever, the indirect analysis could not find any difference on 
QoL scores between SCIT and SLIT [34].
Threshold of allergen exposure to trigger symptoms in an 
environmental exposure chamber or allergen challenge
There were no data to report for this outcome.
Safety
Dranitsaris et  al. undertook an indirect comparison of 
safety between Oralair™, Grazax™ and SCIT [37]. The 
authors reported that there were no significant differ-
ences in the risk of discontinuation due to ARs between 
these three arms (Oralair™ 5.6% (95% CI 3.8–7.3); 
Grazax™ 3.5% (95% CI 1.7–5.2); and SCIT 2.7% (95% CI 
1.3–4.2), respectively).
Dretzke et al. reported that 19% of systemic reactions 
were considered severe after SCIT treatment compared 
with only 2% of systemic reactions after SLIT. Discontin-
uation rates because of AEs were similar between SCIT 
and SLIT (approximately 3%) [36]. Kim et  al. assessed 
safety outcomes for SCIT, SLIT and SCIT versus SLIT 
[35]. Safety of SCIT in children showed that local reac-
tions were common, systemic reactions in 1–30% of 
patients, unspecified or general systemic reactions in 
3–34% of patients, urticaria in 2–19% of patients. No 
anaphylactic reactions or death were reported. Safety 
data on SLIT in children showed that there were local 
reactions in 0.2–50% of patients in the SLIT group and 
6–25% of patients receiving placebo. Systemic reac-
tions were common, but no life-threatening allergic 
reactions were reported. One included study reported 
severe rhinitis and severe asthma symptoms in children 
who exceeded their maximum dose. Reducing the dos-
age of AIT resolved these reactions. Safety of SCIT ver-
sus SLIT showed that there were no systemic reactions 
in patients receiving SLIT; amongst 37 children receiving 
SCIT, however, four experienced systemic reactions (one 
anaphylaxis and three moderate to severe respiratory 
symptoms).
An HTA review reported that local reactions during 
SCIT and SLIT were common, but they resolved spon-
taneously without treatment [34]. Mild or moderate sys-
temic reactions occurred in 4.4% of injections for SCIT. 
Nineteen percent of systemic reactions during SCIT 
treatment were considered to be severe, only 2% of sys-
temic reactions following SLIT were graded as severe. 
Discontinuation due to AEs between these two types of 
AIT were similar (SCIT 3.0% and SLIT 3.4%). No fatali-
ties were reported in any of these trials.
Health economic analysis
Two systematic reviews reported on health economic 
outcomes. Dranitsaris et  al. reported that Oralair™ 
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during the first year of AIT was associated with cost sav-
ings compared with yearly SCIT ($2471), seasonal SCIT 
($948) and Grazax ($1168) [37]. Meadows et al. reported 
that where SCIT and SLIT were directly compared 
against each other, SCIT was found to be both more 
effective and more cost-effective over the long term [34]. 
The sample size of the only trial that directly compared 
the cost-effectiveness of SCIT and SLIT was, however, 
small (n = 64). They also calculated standard incremen-
tal cost-effectiveness ratios (ICERs), which demonstrated 
that both SCIT and SLIT were cost-effective at thresh-
olds of £20,000 per quality-adjusted life-year (QALY). 
However, the included studies were conducted by spon-
sor organizations and there were some issues around 
transparency and/or robustness of parameters for most 
included studies.
SCIT, SLIT, OIT or LNIT for children and adolescents
Effectiveness as assessed by symptom and medication scores
ARC symptom score One systematic review by Roder 
et al., including studies up to 2006, evaluated four types 
of AIT—i.e. SCIT, SLIT, OIT and LNIT—in children and 
adolescents. This review included six SCIT, 11 SLIT, seven 
OIT and four LNIT RCTs. There was insufficient evidence 
that any of these AIT had positive impact on symptom 
scores of children or adolescents [38].
ARC medication score There was insufficient evidence 
in the Roder et  al. review to conclude if AIT delivered 
through these routes had a positive impact on the MS of 
children or adolescents [38].
Secondary outcomes
Safety Local reactions were common; particularly in the 
intervention groups [38]. Systemic reactions were rare; 
only one SLIT trial reported an acute asthma exacerba-
tion that required hospitalization, this occurring in the 
intervention group. However, another SLIT trial reported 
a serious AE in the placebo group. There were no anaphy-
lactic reactions reported.
Assessment of  disease specific quality of  life, threshold 
of  allergen exposure to  trigger symptoms in  an environ-
mental exposure chamber, allergen challenge or health 
economic analysis No data were available for these out-
comes [38].
Discussion
Statement of principal findings
This comprehensive overview of the systematic review 
evidence has found that there is a substantive body of 
high quality evidence indicating that both SCIT and SLIT 
are effective in improving outcomes for patients with 
AR/ARC, although there are less positive efficacy data 
for children treated with SLIT. The safety profile of these 
treatment approaches seems acceptable, with a low risk 
of serious AEs if administered to appropriately selected 
patients and, particularly in relation to SLIT and for 
SCIT, if appropriate resuscitative facilities are available. 
There is limited evidence that these treatment options 
are likely to prove cost-effective. Less is known from sys-
tematic reviews about other routes of delivery of AIT. It 
is also difficult to draw any conclusions on the compara-
tive effectiveness of SCIT versus SLIT versus other treat-
ment routes.
Strengths and limitations of this systematic review
We have undertaken a carefully conducted comprehen-
sive overview of this substantial evidence base. We care-
fully identified relevant MeSH and keywords for AIT in 
patients with AR/ARC, and followed a detailed a priori 
protocol to minimize the risk of bias in our procedures. 
We also took care to ensure that those involved with 
undertaking relevant systematic reviews included in this 
overview were not directly involved in the assessment of 
their own studies.
The main limitations of this overview stems from the 
heterogeneity of populations studied, diversity of AIT 
regimens, allergen preparations, potency and dosage, 
and definitions of outcomes. There is also considerable 
overlap of primary studies included within these reviews, 
approximately a third of included studies are present in 
two or three of the reviews. Almost all the included sys-
tematic reviews reported issues to do with the diversity 
of the underpinning RCT evidence. There was, for exam-
ple, considerable variability in scoring and reporting of 
primary and secondary outcomes including safety data, 
different allergen dosing and treatment schedules [22, 
23, 35]. There was not only methodological diversity in 
the study design but also clinical diversity in the types of 
participants, their allergies, allergens treated, variety in 
dosing and treatment protocols, schedules, geographi-
cal treatment locations, quality, reporting and scoring of 
measured outcomes [22, 23, 28, 35]. As a result of the lack 
of a standardized grading system for reporting adverse 
events associated with AIT in included RCTs, these 
data could only be presented as descriptive data [29, 35]. 
These issues to do with diversity are compounded when 
synthesizing data at the systematic review level and care 
was therefore taken to ensure that we did not over-inter-
pret findings from this initial overview of the literature.
Many of the limitations inherent in reviewing AIT 
relate to the changes in the therapeutic approach over 
the last five decades. While just crude allergen extracts 
were used in the early studies, more modern prepara-
tions are often combined with alum or an adjuvant such as 
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monophosphoryl lipid A/AF or chemically modified into 
an allergoid. There has also been a move to better charac-
terize AIT products to ensure they have a consistent and 
adequate allergen content. We cannot expect all to have 
similar efficacy characteristics. While the published sys-
tematic reviews incorporate this heterogeneity, they do not 
include the large number of recent RCTs assessing potent 
grass pollen and HDM SLIT tablets that are now available.
Given all the heterogeneity in approach, the generally 
positive conclusions of the published systematic review 
hide the underlying heterogeneity between studies. There 
are two key considerations. Firstly, not all products or 
approaches may be equally effective or have equal safety 
records. Secondly, there may be specific subgroups of 
patients who respond better to different approaches. The 
published systematic reviews have struggled to deliver 
useful subgroup analyses, mainly due to heterogeneity 
in study endpoints. With the move to harmonize study 
endpoints, there is now an opportunity to generate meta-
analyses with sufficient numbers of participants to look 
at specific subgroups so as to help to make evidence 
based treatment decisions. It will be important though 
to ensure that results are not biased by studies examining 
older products using less well optimal study designs. Our 
follow-on systematic review will also offer the opportu-
nity to include evidence from the more recent, larger and 
generally better designed clinical trials.
Implications for policy, practice and future research
Systematic overviews of the literature are increasingly 
being used to inform policy deliberations as they can pro-
vide a comprehensive overview of the evidence landscape 
in relation to an important area of enquiry. Our overview 
has done this indicating that there is now substantial 
evidence that AIT—particularly if administered through 
the SCIT and SLIT routes—can be effective in improv-
ing clinically important outcomes in patients with AR/
ARC with an acceptable safety profile. The evidence base 
is far less convincing in children due to lack of high qual-
ity trials in this age group. Also from systematic reviews 
the evidence in seasonal disease due to pollen is more 
consistent than for perennial disease. Importantly, since 
the cut-point date for evaluation in systematic reviews 
a number of large, adequately powered studies provide 
convincing evidence for the efficacy of SLIT for perennial 
mite allergy.
This review demonstrates the need for an updated 
review of AIT therapy, particularly in relation to further 
studies of the comparative effectiveness of these treat-
ment routes, the patients most likely to benefit and least 
likely to experience significant harm, and the cost-effec-
tiveness of AIT. More insights are also needed on how 
the effectiveness, safety and cost-effectiveness of AIT 
compares with other treatment modalities commonly 
used in the treatment of AR/ARC. The follow-on system-
atic review of AIT for ARC will allow these and related 
questions to be answered with considerably more detail 
and through so doing offer the opportunity to draw out 
recommendations for clinical practice.
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